GLP1R and obesity disorder: Incretin-based obesity management medications (OMMs) such as GLP-1 receptor agonists (GLP-1 RAs) and tirzepatide promote weight loss primarily through appetite suppression and delayed gastric emptying, leading to reduced caloric intake and subsequent adiposity reduction [80].